Targacept and Catalyst Biosciences Amend Definitive Merger Agreement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Targacept and Catalyst Biosciences Amend Definitive Merger Agreement

Targacept (TRGT), Catalyst Biosciences Amend Merger Agreement; Considers Wyeth License Termination

May 14, 2015 8:39 AM EDT

Targacept (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced that they have entered into an amendment to the definitive agreement to merge the two companies. Targacept and Catalyst previously announced entering into the definitive merger agreement on March 5, 2015. On April 6, 2015, Targacept disclosed the termination, effective June 1, 2015, of the research and license agreement between Catalyst and Wyeth LLC (a wholly owned subsidiary of Pfizer), which governs the development and commercialization of Catalysts lead product candidate CB 813d/PF-05280602, an engineered Factor VIIa in development for severe hemophilia A and B.... More